A Case for Pharmacare in Canada: Lessons Learned from the UK

Authors

  • Alexandra Kilian
  • Emily Fong
  • Sara Halawa
  • Matthew Hughsam
  • Ben Li

DOI:

https://doi.org/10.15173/m.v1i29.1177

Abstract

In 2014, total drug expenditure in Canada was $33.9 billion, of which a significant proportion (85%) was spent on prescribed drugs.1 Prescription drugs have become an integral component of modern medicine as they can help treat diseases and greatly improve quality of life.2 However, unlike most other countries with a universal health system, Canada does not universally cover prescription drugs.2 While some level of public drug coverage is provided by all provinces and territories in Canada, 58% of prescription drug costs are covered by private health insurance plans or out-of-pocket payments.2 As a result, there is growing interest among the Canadian public to implement a public drug insurance program, often termed “Pharmacare,” to improve access to prescription drugs.2 The United Kingdom (UK) has had a public financing system for health coverage in place, including prescription drugs, for decades. This article explores what Canada can learn from the UK’s successful universal drug coverage program. 

References

CIHI. Spending and Health Workforce Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Pro- grams [Internet]. 2015. Available from: https://secure. cihi.ca/free_products/Prescribed%20Drug%20Spend- ing%20in%20Canada_2014_EN.pdf

Morgan SG, Martin D, Gagnon M-A, Mintzes B, Daw JR, Lexchin J. Pharmacare 2020: The future of drug coverage in Canada. Pharmaceutical Policy Research Collaboration, University of British Columbia; 2015.

Morgan SG, Daw JR, Law MR. Commentary No. 384 Rethinking Pharmacare in Canada [Internet]. Institut C.D. HOWE Institute; 2013. Available from: https://www.cd- howe.org/pdf/Commentary_384.pdf

Pan Canadian Drugs Negotiations Report [Internet]. 2014. Available from: http://www.pmprovincesterri- toires.ca/phocadownload/pcpa/pan_canadian_drugs_ negotiations_report_march22_2014.pdf

Morgan S, Law M, Daw J, Abraham L, Martin D. Esti- mated cost of universal public coverage of prescription drugs in Canada. Canadian Medical Association Journal. 2015;187(7):491-497.

Boothe K. How the Pace of Change Affects the Scope of Reform: Pharmaceutical Insurance in Canada, Australia, and the United Kingdom. Journal of Health Politics, Policy and Law. 2012 Oct 1;37(5):779–814.

Morgan SG, Daw JR. Canadian Pharmacare: Look- ing Back, Looking Forward. Healthcare Policy. 2012 Aug;8(1):14.8.Ntional Pharmacare Strategy. Canadian Federation of Nurses Unions; 2014.

Select Science. Editorial Article: Register Now for our Free Webinar: Analysis of Elemental Impurities in Phar- maceuticals [image on the internet]. 2015 Jul 14 [cited 2016 Mar 15]. Available from: http://www.selectscience. net/editorial-articles/register-now-for-our-free-webinar- analysis-of-elemental-impurities-in-pharmaceuticals/?art ID=38007#sthash.rWLZilqB.dpuf.

Prescription Drug Abuse [Image on the internet]. 2015 [cited 2016 March 21]. Available from: http://www. valleyrecoveryca.com/wp-content/uploads/2015/05/ prescription-drug-abuse-849x564.jpg

Published

2016-04-18

How to Cite

1.
Kilian A, Fong E, Halawa S, Hughsam M, Li B. A Case for Pharmacare in Canada: Lessons Learned from the UK. M [Internet]. 2016 Apr. 18 [cited 2024 Mar. 19];1(29). Available from: https://journals.mcmaster.ca/meducator/article/view/1177

Issue

Section

ForumSpace